U.S. markets closed
  • S&P Futures

    3,721.75
    -10.25 (-0.27%)
     
  • Dow Futures

    29,673.00
    -77.00 (-0.26%)
     
  • Nasdaq Futures

    11,513.00
    -42.75 (-0.37%)
     
  • Russell 2000 Futures

    1,716.40
    -4.40 (-0.26%)
     
  • Crude Oil

    81.71
    -0.44 (-0.54%)
     
  • Gold

    1,662.90
    -7.10 (-0.43%)
     
  • Silver

    18.72
    -0.16 (-0.85%)
     
  • EUR/USD

    0.9682
    -0.0057 (-0.58%)
     
  • 10-Yr Bond

    3.7050
    -0.2590 (-6.53%)
     
  • Vix

    30.18
    -2.42 (-7.42%)
     
  • GBP/USD

    1.0790
    -0.0095 (-0.88%)
     
  • USD/JPY

    144.3260
    +0.2040 (+0.14%)
     
  • BTC-USD

    19,422.73
    +861.35 (+4.64%)
     
  • CMC Crypto 200

    444.12
    +15.34 (+3.58%)
     
  • FTSE 100

    7,005.39
    +20.80 (+0.30%)
     
  • Nikkei 225

    26,245.93
    +71.95 (+0.27%)
     

Investing in Orthocell (ASX:OCC) five years ago would have delivered you a 18% gain

·3 min read

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore, you'd generally like to see the share price rise faster than the market. But Orthocell Limited (ASX:OCC) has fallen short of that second goal, with a share price rise of 18% over five years, which is below the market return. The last year has been disappointing, with the stock price down 15% in that time.

Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business.

Check out our latest analysis for Orthocell

With just AU$1,531,718 worth of revenue in twelve months, we don't think the market considers Orthocell to have proven its business plan. As a result, we think it's unlikely shareholders are paying much attention to current revenue, but rather speculating on growth in the years to come. For example, they may be hoping that Orthocell comes up with a great new product, before it runs out of money.

As a general rule, if a company doesn't have much revenue, and it loses money, then it is a high risk investment. You should be aware that there is always a chance that this sort of company will need to issue more shares to raise money to continue pursuing its business plan. While some such companies do very well over the long term, others become hyped up by promoters before eventually falling back down to earth, and going bankrupt (or being recapitalized).

Orthocell had liabilities exceeding cash by AU$17m when it last reported in June 2022, according to our data. That puts it in the highest risk category, according to our analysis. So the fact that the stock is up 151% per year, over 5 years shows that high risks can lead to high rewards, sometimes. It's clear more than a few people believe in the potential. You can click on the image below to see (in greater detail) how Orthocell's cash levels have changed over time.

debt-equity-history-analysis
debt-equity-history-analysis

Of course, the truth is that it is hard to value companies without much revenue or profit. Given that situation, many of the best investors like to check if insiders have been buying shares. It's usually a positive if they have, as it may indicate they see value in the stock. Luckily we are in a position to provide you with this free chart of insider buying (and selling).

A Different Perspective

We regret to report that Orthocell shareholders are down 15% for the year. Unfortunately, that's worse than the broader market decline of 1.9%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Longer term investors wouldn't be so upset, since they would have made 3%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. It's always interesting to track share price performance over the longer term. But to understand Orthocell better, we need to consider many other factors. Take risks, for example - Orthocell has 4 warning signs (and 1 which is concerning) we think you should know about.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on AU exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here